APRISO

Mesalamine is prescribed to manage ulcerative colitis, a specific bowel disease. It effectively alleviates symptoms associated with ulcerative colitis, such as diarrhea, rectal bleeding, and abdominal pain. Mesalamine is classified as an aminosalicylate medication, working to reduce inflammation in the colon.

Discontinuing Apriso treatment is not anticipated to lead to side effects, as withdrawal symptoms have not been documented in clinical studies of the drug. However, ceasing Apriso usage can result in the reactivation of ulcerative colitis symptoms.

Mesalazine can be taken for extended periods, but your doctor will monitor your kidney function during the treatment. Although rare, mesalazine can potentially lead to kidney problems. Typically, these kidney assessments occur every three months during the initial year of treatment.

Seek immediate medical attention if you experience lower back or side pain, decreased urination frequency or volume, bloody urine, increased thirst, loss of appetite, nausea, vomiting, unusual fatigue, facial or limb swelling, weight gain, or breathing difficulties.

Apriso, an extended-release capsule containing mesalamine, is categorized as an aminosalicylate anti-inflammatory drug. It is prescribed for the treatment of ulcerative colitis, proctitis, and proctosigmoiditis, and can also serve to prevent the recurrence of ulcerative colitis symptoms.

Do not use mesalamine if you have allergies to mesalamine, aspirin, sulfasalazine, or salicylates, including products like Disalcid, Doans Pills, Dolobid, Kaopectate, Nuprin Backache, Pepto-Bismol, Tricosal, Trilisate, and others.

Apriso contains the active ingredient mesalamine. A generic version of Apriso capsules is available under the name mesalamine. It is important to note that Apriso capsules are a prolonged-release formulation of mesalamine.

No, Apriso is not associated with weight gain based on clinical trials. However, it is possible that you may gain weight if Apriso effectively maintains remission of your ulcerative colitis symptoms.

Mesalamine is used to treat and prevent flare-ups of mild to moderately active ulcerative colitis, an inflammatory bowel disease. It operates within the intestines to mitigate inflammation and other symptoms of the condition. This medication is obtainable solely through a prescription from your physician.

If you have liver disease, consult your doctor before using APRISO. Instances of liver failure have been reported in patients with liver disease who took mesalamine. Additionally, avoid taking APRISO concurrently with antacids, as the dissolution of APRISO granules relies on stomach acidity.

Common drug reactions encompass fever, nausea, diarrhea, and abdominal pain, although exacerbation of ulcerative colitis has been rarely documented. This study underscores the necessity of ruling out mesalamine as the causative agent in cases of ulcerative colitis exacerbations.

Mesalazine is suitable for long-term use. Nonetheless, your doctor will assess your kidney function throughout the treatment. Kidney issues attributable to mesalazine are infrequent, and these evaluations typically occur every three months during the initial year.

Mesalamine falls under the category of anti-inflammatory medications. Its mechanism of action involves inhibiting the production of specific substances responsible for causing inflammation in the body.

It is recommended to take Apriso in the morning due to its delayed-release and extended-release properties. Apriso capsules release the medication gradually over a specific timeframe after ingestion.

For once-a-day treatment, four APRISO capsules should be taken in the morning, with or without food.

Avoid exposure to sunlamps and tanning beds while using this medication. Simultaneous use of antacids (e.g., Amphojel , Maalox , Mylanta , Tums ) and Apriso capsules may alter the rate of medicine release in your body. Ensure that any healthcare provider or dentist you visit is aware of your mesalamine usage.

This medication may potentially lead to kidney problems, including kidney stones. If you already have kidney issues, taking Apriso could exacerbate them. Your doctor may closely monitor your kidney function or recommend an alternative medication, especially if your kidney problems worsen.

Possible side effects of this medication include stomach upset, nausea/vomiting, constipation, headache, or joint/muscle pain. If any of these effects persist or worsen, promptly inform your doctor or pharmacist. In some cases, you may notice whole or partial tablets/capsules in your stool.

No, weight gain was not reported as a side effect in clinical studies of Apriso. It’s important to note that Apriso is designed to keep ulcerative colitis (UC) symptoms in remission, which means a period when you are symptom-free.

Do I need to take APRISO with an empty stomach or with food? You can take APRISO with or without food. It passes through the stomach without complete absorption.

Possible side effects may include burping, constipation, nausea, vomiting, stomach pain, diarrhea, gas, dizziness, cold symptoms like stuffy nose, sneezing, sore throat, back pain, headache, rash, or abnormal liver function tests.

The cost for a supply of 120 capsules of Apriso oral extended-release capsules (0.375 g) is approximately $547, depending on the pharmacy you visit.

Mesalamine suppositories are administered rectally and should not be cut or broken. They should be used once daily at bedtime for a duration of 3 to 6 weeks. It is unknown whether mesalamine suppositories are safe and effective for use beyond 6 weeks.

There were no interactions found between Apriso and Tylenol when considering drug interactions.

Mesalamine is used to treat and prevent flare-ups of mild to moderately active ulcerative colitis, an inflammatory bowel disease. It operates within the intestines to reduce inflammation and alleviate other symptoms of the condition. This medication is available solely by prescription from your doctor.

To use Mesalamine ER 500 Mg Capsule, Extended Release Inflammatory Bowel Agents, take it orally as directed by your physician, typically four times daily. If you are taking the capsule form of this medication, you may take it with or without food.

Brand names for mesalamine include Asacol, Asacol HD, Canasa, Canasa Pac, Delzicol, Lialda, Pentasa, Rowasa, Rowasa Sulfite Free, and Zaldyon.

Balsalazide has been found to be more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis, as reported in Gastroenterology.

For once-a-day treatment, it is recommended to take four APRISO capsules in the morning, with or without food.

Lialda is approved for use in adults with UC to induce or maintain remission, while Apriso is approved solely for the maintenance of remission in adults with UC.

Another form of 5-ASA is mesalamine, which does not contain a sulfa group. Approximately 90% of individuals with sulfasalazine intolerance can tolerate mesalamine. Mesalamine-based oral 5-ASA agents include Asacol HD, Pentasa, Lialda, Apriso, and Delzicol.

On May 13, 2022, Allergan Pharmaceuticals International Ltd. informed the FDA that ASACOL HD (Mesalamine) Delayed-Release Tablet, 800 mg, was being discontinued, leading the FDA to move the drug product to the ‘Discontinued Drug Product List’ section of the Orange Book.

Mesalamine is a prescription medication indicated for inducing remission in patients with active, mild to moderate ulcerative colitis and maintaining remission of ulcerative colitis. It is available under various brand names, including Asacol HD, Pentasa, Delzicol, Lialda, and Apriso.

Mylan launched an AB-rated generic version of Bausch Health’s Apriso (mesalamine) 375 mg extended-release capsules on November 27, 2019. Apriso is approved for maintaining remission of ulcerative colitis in patients aged 18 and older.